The Manufacturers Life Insurance Company Acquires 8,485 Shares of ChromaDex Co. (NASDAQ:CDXC)

The Manufacturers Life Insurance Company grew its holdings in ChromaDex Co. (NASDAQ:CDXC) by 75.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,732 shares of the company’s stock after buying an additional 8,485 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in ChromaDex were worth $72,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Merriman Wealth Management LLC acquired a new position in ChromaDex during the 2nd quarter worth $32,000. SG Americas Securities LLC acquired a new position in shares of ChromaDex during the third quarter valued at $61,000. Marshall Wace LLP bought a new position in ChromaDex in the second quarter valued at about $56,000. Dimensional Fund Advisors LP acquired a new stake in ChromaDex in the second quarter worth about $88,000. Finally, Rhumbline Advisers bought a new stake in ChromaDex during the 2nd quarter worth about $124,000. 15.41% of the stock is owned by institutional investors.

ChromaDex Trading Down 2.4 %

ChromaDex stock opened at $6.00 on Wednesday. The firm has a market capitalization of $458.30 million, a P/E ratio of 592.00 and a beta of 2.16. The business has a 50-day moving average of $5.71 and a 200-day moving average of $4.01. ChromaDex Co. has a 1 year low of $1.34 and a 1 year high of $7.97.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter in the previous year, the company earned ($0.01) earnings per share. Research analysts anticipate that ChromaDex Co. will post 0.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. StockNews.com cut shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. HC Wainwright lifted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Finally, Roth Mkm increased their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

Insider Activity

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the transaction, the director now owns 244,179 shares in the company, valued at $1,511,468.01. The trade was a 13.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.64% of the stock is owned by company insiders.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.